Periodic Reporting for period 1 - TAFALGIE (The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance)

A spin-off company of the CNRS/IBDM, founded in 2020 in Marseille, France, Tafalgie Therapeutics aims to capitalize on more than 15 years of fundamental academic research dedicated to understanding the fundamental molecular and cellular mechanisms of acute and chronic pain...